PT Indofarma Tbk, together with its subsidiaries, manufactures and markets pharmaceutical products in Indonesia. The company trades in and distributes drugs, medical devices, medical supplies, extracts, and herbals; and operates laboratory. It also provides COVID-19 test services, including rapid diagnostic test antigen; reverse transcription polymerase chain reaction, and genose. The company also exports its products. The company was formerly known as PT Indofarma (Persero) Tbk. PT Indofarma Tbk was founded in 1918 and is headquartered in Bekasi, Indonesia. PT Indofarma Tbk operates as a subsidiary of PT. Bio Farma.
Nama Perusahaan | Indofarma Tbk. |
Sektor | Kesehatan |
Sub Sektor | Farmasi & Riset Kesehatan |
Industri | Farmasi |
Sub Industri | Farmasi |
Jumlah saham beredar | 3,099,267,500 lembar |
Market Cap | 960,772,925,000 | |
Sales | 10,273,694,122,215,000 | (IDR) |
Net Income | -6,555,789,816,885,000 | (IDR) |
Equity | 86,359,126,524 | (IDR) |
Free Cash | 0 | (IDR) |
Item | Highlight | Score |
---|---|---|
Market Cap vs Equitas | Nilai market Cap lebih besar dari equitas | 0 |
PER | Valuasi PER < 10 | 1 |
Net Profit | Rasio profitabilitas kurang dari 10% | 0 |
Return On Equity | Return On Equity kurang bagus, < 15% | 0 |
Rasio Hutang | Rasio DER lebih dari 1 | 0 |
Current Ratio | Liabilities lebih besar daripada aset lancar | 0 |
Harga Wajar | Harga saham masih undervalued (-88,411) | 1 |
tahun | TTM | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|
Revenue | 684,912,941,481 | 1,144,108,230,742 | 2,901,986,532,879 | 1,715,587,654,399 | 1,359,175,249,655 | 1,592,979,941,258 |
Gross Profit | -168,008,168,842 | -135,724,154,212 | 442,874,585,841 | 394,622,939,535 | 247,652,013,477 | 264,234,685,304 |
Operating Income | -506,450,688,820 | -448,362,980,468 | 53,093,068,227 | 53,215,166,410 | 22,745,920,864 | -21,590,118,706 |
Pretax Income | -540,913,429,773 | -517,557,861,610 | 8,773,199,052 | 18,081,602,176 | 9,745,969,307 | -25,298,215,467 |
Net Income | -437,052,654,459 | -428,462,954,238 | -37,580,639,615 | 27,580,910 | 7,960,962,724 | -32,735,901,429 |
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Aset | 1,534,000,446,508 | 2,011,879,396,142 | 1,713,334,658,849 | 1,383,935,194,386 | 1,442,350,608,575 |
Aset Lancar | 863,577,052,312 | 1,411,390,099,989 | 1,134,732,820,080 | 829,103,602,342 | 867,493,107,334 |
Other Current Asset | 0 | 281,889,543,860 | 227,877,827,113 | 212,082,226,170 | 206,046,930,975 |
Total Liabilities | 1,447,651,934,795 | 1,503,569,486,636 | 1,283,008,182,330 | 878,999,867,350 | 945,703,748,717 |
Total Equities | 86,359,126,524 | 508,295,782,392 | 430,321,799,055 | 504,933,639,526 | 496,646,167,030 |
TTM | 2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|---|
Kas dari Aktivitas Operasi | -78,120,732,432 | -112,573,636,115 | 92,899,478,946 | 46,547,903,552 | 37,184,640,411 | -70,390,895,931 |
Kas dari Aktivitas Investasi | -1,875,300,520 | -11,769,832,921 | -114,411,412,251 | -9,041,943,818 | 60,090,678,460 | -46,400,057,765 |
Kas dari Aktivitas Pembiayaan | 68,775,889,384 | 13,327,575,869 | 244,148,898,768 | -30,681,231,919 | -75,026,516,980 | 63,805,377,524 |
Arus Kas Bebas | 0 | 0 | 0 | 0 | 0 | 0 |